
    
      Randomized multicenter clinical trial with two parallel groups. Patients with major
      depression (unipolar or bipolar), who have remitted with electroconvulsive therapy (ECT) are
      eligible. All patients receive pharmacotherapy (venlafaxine target dose 300mg/day, and
      lithium target dose 0,5-0,8 mmol/L). The intervention is continuation unilateral ECT weekly
      for the first 6 weeks thereafter every 2 weeks for one year. Depressive relapse is the
      primary outcome measure.
    
  